文献速递类风湿关节炎

对生物制剂治疗无效的活动性类风湿关节炎患者使用乌帕替尼应答的长期可持续性:SELECT-BEYOND 研究长达 5 年的结果

Long-term sustainability of response to upadacitinib among patients with active rheumatoid arthritis refractory to biological treatments: results up to 5 years from SELECT-BEYOND.
PubMed 文献 · RMD Open · 2024-07-24

SELECT-BEYOND 3 期试验评估乌帕替尼 15 mg 对生物制剂改善病情抗风湿药无效或不耐受(bDMARD-IR)的类风湿关节炎患者的长期应答可持续性。5 年研究期间,45%(104/229)和 79%(172/219)的患者分别在任何时点达到 CDAI 缓解或 CDAI 低疾病活动度(LDA)。达到 CDAI 缓解/LDA 者中,25%/43% 在首次应答后维持至 240 周随访。

要点

  • bDMARD-IR 患者中 79%(172/219)在任何时点达到 CDAI LDA,45%(104/229)达到 CDAI 缓解。
  • 达到 CDAI 缓解/LDA 者中,25%/43% 维持初始应答至 240 周随访。
  • 多数失去缓解或 LDA 的患者截至数据截止日能重新获得该应答。

核心结论

  • 超过四分之三的 bDMARD-IR 患者使用乌帕替尼达到 CDAI LDA,其中近半数维持 LDA 至 240 周随访。
  • 近半数患者达到缓解,达到缓解者中约四分之一维持缓解。

研究设计与样本

  • SELECT-BEYOND 3 期试验,纳入对生物制剂改善病情抗风湿药无效或不耐受(bDMARD-IR)的类风湿关节炎患者。
  • 患者在接受背景传统合成改善病情抗风湿药(csDMARDs)基础上,每日一次接受乌帕替尼 15 mg 或安慰剂治疗。
  • 完成第 24 周访视的患者可进入最长 5 年的长期扩展研究。
  • 应答可持续性评估至第 260 周,纳入所有接受获批乌帕替尼 15 mg 剂量的患者,包括随机分配至乌帕替尼 15 mg 者及第 12 周从安慰剂转换至乌帕替尼 15 mg 者。

主要发现

  • 5 年研究期间,45%(n=104/229)的患者达到 CDAI 缓解,79%(n=172/219)达到 CDAI LDA。
  • 达到 CDAI 缓解/LDA 者中,25%/43% 在首次达到应答后维持至 240 周随访。
  • 多数失去缓解或 LDA 的患者截至数据截止日能重新获得该应答。
  • SDAI 和 DAS28(CRP)观察到相似的总体结果。
  • 未识别出强应答预测因素。

关键数值与推荐

  • 应答可持续性基于达到 CDAI、SDAI 和 DAS28(CRP)目标进行评估。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate the long-term sustainability of response to the Janus kinase inhibitor upadacitinib among patients with rheumatoid arthritis and an inadequate response or intolerance to biological disease-modifying antirheumatic drugs (bDMARD-IR) in the SELECT-BEYOND phase 3 trial. METHODS: Patients on background conventional synthetic DMARDs (csDMARDs) were treated once daily with upadacitinib 15 mg or placebo. Patients who completed the week 24 visit could enter a long-term extension of up to 5 years. The sustainability of response was assessed based on achievement of Clinical Disease Activity Index (CDAI), Simplified Disease Activity Index (SDAI) and Disease Activity Score 28-joint count using C-reactive protein (DAS28 (CRP)) targets and evaluated up to week 260 in all patients receiving the approved upadacitinib 15 mg dose, including those randomised to upadacitinib 15 mg and those who switched from placebo to upadacitinib 15 mg at week 12. RESULTS: In this bDMARD-IR population, 45% (n=104/229) and 79% (n=172/219) of patients treated with upadacitinib 15 mg plus background csDMARD(s) achieved CDAI remission or CDAI low disease activity (LDA) at any point during the 5-year study, respectively. Of those who achieved CDAI remission/LDA, 25%/43% maintained their initial response through 240 weeks of follow-up after first achieving response. Most patients who lost remission or LDA were able to recapture that response by the cut-off date. Similar overall results were observed for SDAI and DAS28 (CRP). No strong predictors of response were identified. CONCLUSIONS: Over three-quarters of bDMARD-IR patients achieved CDAI LDA with upadacitinib, and almost half of those maintained LDA through 240 weeks of follow-up. Remission was achieved by nearly half of all patients and maintained in approximately a quarter of those achieving remission. TRIAL REGISTRATION NUMBER: NCT02706847.

来源:RMD Open,查看原文。版权归原作者所有。

引用

  1. van Vollenhoven RF, Hall S, Wells AF, et al. Long-term sustainability of response to upadacitinib among patients with active rheumatoid arthritis refractory to biological treatments: results up to 5 years from SELECT-BEYOND. RMD Open. 2024. PMID: 39053948. doi:10.1136/rmdopen-2023-004037

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。